Table 1 Patients’ characteristics
| Â | RT group (%) | CRT group (%) | Referent group (%) |
|---|---|---|---|
| Â | N=101 | N=101 | N=101 |
Age | Â | Â | Â |
   ≥65, <70 | 78 (77.2) | 78 (77.2) |  |
   ≥70 | 23 (22.8) | 23 (22.8) |  |
   Median | 68 | 69 | 45 |
   Range | 65-80 | 65-77 | 18-65 |
Gender | Â | Â | Â |
   Male | 81 (80.2) | 81 (80.2) | 81 (80.2) |
   Female | 20 (19.8) | 20 (19.8) | 20 (19.8) |
Histology | Â | Â | Â |
   WHO type I | 1 (1.0) | 1 (1.0) | 1 (1.0) |
   WHO type II | 10 (9.9) | 14 (13.9) | 12 (11.9) |
   WHO type III | 90 (89.1) | 86 (85.1) | 88 (87.1) |
PS score (ECOG) | Â | Â | Â |
   0 | 0 (0) | 1 (1.0) | 1 (1.0) |
   1 | 101 (100) | 99 (98.0) | 99 (98.0) |
   2 | 0 (0) | 1 (1.0) | 1 (1.0) |
ACE-27 score | Â | Â | Â |
   0 | 64 (63.4) | 67 (66.3) | 70 (69.3) |
   1 | 26 (25.7) | 23 (22.8) | 22 (21.8) |
   2 | 10 (9.9) | 10 (9.9) | 8 (7.9) |
   3 | 1 (1.0) | 1 (1.0) | 1 (1.0) |
Stage method | Â | Â | Â |
   CT | 37 (36.6) | 37 (36.6) | 37 (36.6) |
   MRI | 64 (63.4) | 64 (63.4) | 64 (63.4) |
T stage * | Â | Â | Â |
   T1-2 | 19 (18.8) | 26 (25.7) | 23 (22.8) |
   T3-4 | 82 (81.2) | 75 (74.3) | 78 (75.2) |
N stage * | Â | Â | Â |
   N0-1 | 66 (65.3) | 46 (45.5) | 53 (52.5) |
   N2-3 | 35 (34.7) | 55 (54.5) | 48 (47.5) |
Overall stage * | Â | Â | Â |
   III | 50 (49.5) | 47 (46.5) | 47 (46.5) |
   IVa-b | 51 (50.5) | 54 (53.5) | 54 (53.5) |
RT technique | Â | Â | Â |
   2D conventional RT | 93 (92.1) | 94 (93.1) | 92 (91.1) |
   3D conformal RT | 1 (1.0) | 1 (1.0) | 1 (1.0) |
   IMRT | 7 (6.9) | 6 (5.9) | 8 (7.9) |
RT dose (median) | Â | Â | Â |
   NP | 70 | 70 | 70 |
   LN | 60 | 62 | 60 |